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Abstract The progression of Alzheimer’s disease (AD) has
been associated with astrocytes-induced neuroinflammation.
However, the detailed mechanism of astrocytes associated with
learning impairments and neuronal loss in AD is poorly defined.
Here, we provide novel evidences that astrocytic miR-135a is
critical for neuronal viability and spatial learning ability in vivo.
The AppTg/Cebpd−/− mice showed a spatial learning improve-
ment compared with the APPswe/PS1/E9 bigenic (AppTg)
mice. miR-135a was found to be a CCAAT/enhancer binding
protein δ (CEBPD) responsive miRNA and can repress the
transcription of thrombospondin 1 (THBS1) / Thbs1 (mouse)
via its 3′-untranslated region (3′UTR). We used different exper-
imental approaches to attenuate the expression of CEBPD/
Cebpd (mouse) or miR-135a in astrocytes and found the follow-
ing results: increase in THBS1/Thbs1 expression, decrease in
neuronal apoptosis, and increase in growth of neurites. Impor-
tantly, injection ofmiR-135a antagonist (AM135a) into the brain
of AppTg mice was found to prevent neuronal apoptosis and
improved the spatial learning ability. Together, our findings
demonstrate a critical function for the astrocytic CEBPD, and
point to miR-135a antagonist as an attractive therapeutic target
for the treatment of Alzheimer’s disease.
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Introduction
Neuroinflammation is a prominent feature of Alzheimer’s dis-
ease (AD) and has been suggested to play a role in AD pro-
gression [1–3]. Current consensuses suggest that neuroinflam-
mation can lead to neuronal dysfunction, death, and ultimately
severe cognitive impairment of AD patient [4, 5]. Accumulated
results found that the reactive astrocytes are involved in the
induction of neuroinflammation [6–8]. Astrocytes are original-
ly thought to be supportive glial cell components in the central
nervous system (CNS), which provide energy metabolites to
neurons and regulate neuron maturation [9, 10]. Recently, it
has also been recognized that the secretory function of astro-
cytes can further regulate neuronal survival and neuronal repair
after CNS injury [11]. Thrombospondin 1 (THBS1) is a
multimeric extracellular matrix glycoprotein [12] secreted by
astrocytes, which can function in neuronal dendritic growth,
axonal sprouting, and synaptogenesis [13–15].
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CCAAT/enhancer binding protein delta (CEBPD) is a piv-
otal transcription factor in brain inflammation and is a member
of CCAAT/enhancer binding protein (C/EBP) family [16].
CEBPD is responsive to many proinflammatory cytokines
involved in the pathogenesis of neurodegenerative diseases
[17, 18, 1] such as interleukin-1β (IL-1β), interleukin-6 (IL-
6), and tumor necrosis factor α (TNFα) [19, 1]. Interestingly,
the expression of CEBPD was found to be increased in age-
associated disorders including AD [20], atherosclerosis [21],
type 2 diabetes [22], and RA [23]. We have previously tried to
attenuate the expression of CEBPD and found that it can lead
to better prognosis in mouse model of AD [24, 25]. The better
AD prognosis has been attributed to attenuation in endothelial
cell-mediated angiogenesis and macrophage-mediated phago-
cytosis of damaged neurons and increase in anti-apoptosis
effect of astrocytes [26, 25, 27].
The role of CEBPD in the pathogenesis of AD has been
investigated, but there are limited studies on the signal trans-
duction pathway that CEBPD undertook in the pathogenesis of
AD. Specifically, we were interested to investigate the down-
stream miRNA targets of astrocytic CEBPD and how it can
lead to neuroinflammation. miRNAs are small non-coding
RNA that regulate gene expression post-transcriptionally by
base-pairing to mRNA [28]. There is evidence that imbalanced
in the expression of miRNAs can lead to neurodegenerative
diseases [29–31] and differential expression of miRNA in as-
trocytes and neurons after ischemic injury [32].
Glia-mediated neurotoxicity and neuroprotection have been
suggested to be involved in the cognitive loss of AD patients.
However, astrocytes participate in neuronal loss and conse-
quent learning impairments in AD is poorly defined. Transcrip-
tion factor CEBPD is significantly activated in astrocytes of
AD patients and AppTg mice [20, 26]. In this study, the deficit
of spatial learning ability in AppTg mice was ameliorated in
AppTg/Cebpd−/− mice. Therefore, the investigation of CEBPD
biology in astrocytes, especially in regulation of neurotrophic
factors, could provide a new insight for understanding the com-
munication of astrocytes and neuronal cells in AD pathogene-
sis. Our results suggested that astrocytic CEBPD activation
results in the impairment of spatial learning ability through
activating miR-135a to suppress neurotropic factor THBS1.
Importantly, the miR-135a antagonist (AM135a) can effective-
ly recuse the spatial learning ability of AppTg mice.
Materials and Methods
Materials
α-Tubulin antibody (T6199) was purchased from Sigma (St.
Louis, MO, USA) and CEBPD antibody (SC-636) was pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). NeuN antibody (MAB377) was purchased fromMerck
Millipore. The cleaved caspase 3 antibody (#9661) was pur-
chased from Cell Signaling Technology (Danvers, MA,
USA). The antibodies against THBS1 (GTX21823) and
MAP2 (GTX11267) were purchased from GeneTex (Irvine,
CA, USA). Secondary antibodies used in immunofluores-
cence analysis were goat anti-mouse/rabbit IgG (H + L) sec-
ondary antibody, Alexa Fluor® 488 conjugate (A-11001/A-
11008) and goat anti-mouse/rabbit IgG (H + L) secondary
antibody, Alexa Fluor® 568 conjugate (A-11031/A-11011)
obtained from Invitrogen (Carlsbad, CA, USA). Secondary
antibodies used in Western blot analysis were goat anti-
mouse/rabbit IgG, peroxidase-conjugated (AP-124P/AP-
132P) purchased from Merck Millipore. TRIzol RNA extrac-
tion reagent, Dulbecco’s modified Eagle’s medium (DMEM),
and Opti-MEM medium were obtained from Invitrogen
(Carlsbad, CA, USA). All oligonucleotides were synthesized
by MDBio Inc. (Taipei, Taiwan). Fetal bovine serum
(FBS) was purchased from HyClone Laboratories (Lo-
gan, UT, USA).
Animals
The Cebpd-deficient mice were a gift from Dr. E. Sterneck.
The APPswe/PS1/E9 transgenic (AppTg) mice were obtained
from Jackson Laboratory (Bar Harbor, ME, USA, stock no.
004462). The AppTg mice were crossed with Cebpd−/− mice
on the C57BL/6 genetic background. Female mice heterozy-
gous for AppTg mice was intercrossed with Cebpd−/− homo-
zygous mice; the offspring (AppTg+/−/Cebpd+/−) were then
bred to each other to produce the AppTg/Cebpd−/−mice in this
study. The 12 month aged wild-type (Cebpd+/+), AppTg, and
AppTg/Cebpd−/− mice were used to perform the Morris water
maze in this study. The N number of each group is 3–5.
Cell Culture and Preparation of Primary Cells
U373MG (human glioblastoma-astrocytoma) and SH-SY5Y
(human neuroblastoma) cells were cultured in DMEM or
DMEM/F12 containing 10 % FBS, 100 μg/mL streptomycin,
and 100 units/ml penicillin. For the preparation of primary
mouse astrocytes and cortical neuron, the cortex were re-
moved from P0 mouse brains and dissected in HEPES-
buffered saline, carefully stripped of their meninges and
digested with 0.25% trypsin in Hanks’Balanced Salt Solution
(Invitrogen, Carlsbad, CA, USA) for 10 min at 37 °C.
Trypsinization was stopped by adding an equal volume of
culture medium. Cortical neurons were dissociated specifical-
ly by trituration in neurobasal plus B27 supplemented with
1 % L-glutamine and 1 % penicillin medium and passage
through a 70-μm nylon strainer. The solution was pelleted
(10 min, 200 g) and then resuspended in culture medium
and brought to a single cell suspension by repeated pipetting
followed by passage through a 70-μm nylon strainer. Later,
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astrocytes were seeded on plates coated with laminin (20 μg/
mL, Invitrogen). Laminin-coating favors astroglial growth
and inhibits microglial growth [33]. Cortical neurons were
then plated on glass slides or plastic culture dishes coated with
poly-L-lysine (Sigma).
Immunofluorescence Analysis
The frozen mouse brain sections were treated with protein
blocker/antibody diluents (Bio SB) for 1 h. In the same buffer
solution, the sections were incubated overnight with primary
antibodies at 4 °C. These primary antibodies included caspase
3 and MAP2. For the staining of cultured cells, primary cor-
tical neuron cells were post-fixed in 4 % paraformaldehyde in
phosphate-buffered saline (PBS) for 10 min, followed by
0.5 % Triton X-100 in PBS at room temperature for 10 min.
The fixed neuron cells were further incubated with primary
antibodies overnight against target proteins in 3 % bovine
serum albumin at 4 °C. Pretreated slides of the tissue sections
or neuron cells were washed with 0.05 % Tween-20 in PBS
and then incubated withAlexa488- or 568-conjugated second-
ary antibodies for 1 h then washed again with 0.05 % Tween-
20 in PBS. Next, the glass slides were counter-stained and
mounted with ProLong Gold antifade reagent with 4′, 6-
diamidino-2-phenylindole for immunofluorescence
microscopy.
The Preparation of Conditioned Medium
For the collection of CM, wild-type and Cebpd-deficient pri-
mary astrocytes were pretreated with or without 5 ng/mL IL-
1β (Invitrogen, Carlsbad, CA, USA) for 6 h. Later, the IL-1β
pretreated cells were washed by PBS and replaced in the
serum-free medium. After additional 12 h, the supernatants
were collected after centrifuge at 5000 g for conditioned
media.
Cell Survival Assays
For the neuronal cell survival assay, P0 wild-type and Cebpd-
deficient primary cortical neurons were plated and maintained
for 7 days. The experimental cells were grown in the condi-
tioned medium as mentioned above for 48 h. Next, the media
was removed and replaced with di lu ted 3-(4 ,5-
cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) reagent for 4 h. The samples were thenmeasured spec-
trophotometrically at 595 nm using an enzyme-linked immu-
nosorbent assay plate reader.
Microarray Analysis
Total RNAs were isolated using the TRIzol RNA extraction
reagent. Samples were validated with Agilent Human and
Primate miRNA one array (Phalanx Biotech., Taipei, Taiwan),
following the manufacturers’ protocols. All processes were
performed by Phalanx Biotech Company (Taipei, Taiwan).
Good quality signals were obtained by filtering for scores of
p value <0.05 in all replicates,M value of >6 in all signals, and
more than 1.5-fold change.
RNA Isolation, Reverse Transcription, and Quantitative
Real-Time PCR
Total RNAs were isolated using the TRIzol RNA ex-
traction reagent and subjected to reverse transcription
with SuperScriptTM III. Specific primers used for the
RT-PCR analysis are as follows: for GAPDH (20 cycles
a n d p r o d u c t s i z e : 5 7 6 b p ) , 5 ′ -
C C AT CAC CAT C T T C CAGGAG - 3 ′ a n d 5 ′ -
CCTGCTTCACCACCTTCTTG-3′; for THBS1 (28 cycles
a n d p r o d u c t s i z e : 3 7 6 b p ) , 5 ′ -
G C T CAGAG TGGATG T TATGG - 3 ′ a n d 5 ′ -
GGGAATACTTCTCTGCAGAG-3′; for Thbs1 (28 cycles
a n d p r o d u c t s i z e : 1 9 2 b p ) , 5 ′ -
C CAAAGCCTGCAAGAAAGAC - 3 ′ a n d 5 ′ -
CCTGCTTGTTGCAAACTTGA-3′; for CEBPD (26 cy-
c l e s a n d p r o d u c t s i z e : 2 6 7 b p ) , 5 ′ -
A GCGCAACAACATCGCCGTG - 3 ′ a n d 5 ′ -
GTCGGGTCTGAGGTATGGGTC-3′; and for Cebpd
( 2 6 c y c l e s a n d p r o d u c t s i z e : 4 2 9 b p ) , 5 ′ -
AT C G C T G C A G C T T C C TAT G T- 3 ′ a n d 5 ′ -
GGTTAAGCCCGCAAACATTA-3′ The PCR products
were separated by electrophoresis in 1 % agarose gels
and visualized with ethidium bromide staining. For qRT-
PCR, the resultant cDNA was mixed with SYBR Premix
ExTaq kit and appropriate primers, and quantitative
PCR was performed with Thermocycler C1000 (Bio-
Rad, Hercules, CA, USA). Forty cycles were set for
qRT-PCR program and the abundances of interested
gene expression were calculated following the formula
(2 -ΔΔCt) suggested in the instruction of qRT-PCR kit
(Applied Biosystems). Specific primers used for the
qRT-PCR analysis are as follows: for GAPDH, 5′-
C CACCCAGAAGACTGTGGAT- 3 ′ a n d 5 ′ -
AAGGTCATCCCTGAGCTGAA-3′; for THBS1, 5′-
G A C C TGCCACAT T CAGGAG T- 3 ′ a n d 5 ′ -
CTTTCTTGCAGGCTTTGGTC-3 ′; for Thbs1 , 5 ′-
C CAAAGCCTGCAAGAAAGAC - 3 ′ a n d 5 ′ -
CCTGCTTGTTGCAAACTTGA-3′; for miR-135a re-
v e r s e t r a n s c r i p t i o n ( R T ) p r i m e r , 5 ′ -
CTCAACTGGTGTCGTGGAGTCGGCAATCACTTGA-
GTCACATAG-3 ′; and for miR-135a forward, 5 ′-
A C A C T C C A G C T C A G TAT G G C T T T T TA
T T C C T A T G T - 3 ′ a n d r e v e r s e , 5 ′ -
CTCAACTGGTGTCGTGGAGTCGGCAATTCAG-3′.
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TaqMan Reverse Transcription-PCR for miRNA
Quantification
Total RNAwas isolated using TRIzol according to the manu-
facturer’s protocol, reverse-transcribed using a TaqMan®
microRNA reverse transcription kit, and subjected to real-
time PCR using a TaqMan® microRNA assay kit (Applied
Biosystems).
Cloning and Mutagenesis
The 3′-UTRs of THBS1 and Thbs1 genes and 5′-
flanking region of GLYCTK-AS1-001 gene (host gene
of intronic miR-135a) were cloned from U373MG cells
by using the DNeasy Tissue Kit (QIAGEN, Düsseldorf,
Germany) and PCR. The following primers were used
for PCR and cloning: GLYCTK-AS1-001 forward, 5′-
KpnI-CGGGGTAC CCCGAGCCCCCTGCAACCT-3′
a n d r e v e r s e p r i m e r 5 ′ X h o 1 -
CCGCTCGAGCGGACCGAGAGATAAAGCCTG-3′;
T H B S 1 - 3 ′ U T R f o r w a r d , 5 ′ X b a l I -
TCTAGATGTAGCTTGTGCAGATGT-3′ and reverse, 5′
EcoRV-CTGAGATATCTATTCCAATGGCAATGAG-3′;
Thbs1-3 ′UTR (1w) forward , 5 ′Xbal1-TCTAGA
GCCAATCATAACCAGC-3′ and reverse, 5′EcoRV-
GATATCGTATAGAAGTTCCACCTTTGT-3′. These
PCR fragments were subcloned into pGL3-promoter or
pGL3-basic vector for further reporter assay. Mutant re-
porter plasmids were constructed by the site-directed
mutagenes is fo l lowing the ins t ruc t ions of the
QuikChang Site-directed Mutagenesis Kit (Stratagene,
CA, USA) with the primers of THBS1-3′UTR mutant,
5 ′ - A A A T T G C A A A G A A A G A T A T
C A G G T C T T C A AT A C T G T - 3 ′ , M 1 , 5 ′ -
CTCCTTGTAATGGATATCAGGAGTACTCTA-3′, or
M2, 5′-GTTTGCTTTTGGGATATCCAAAGCGCCTAT-3′.
DNAVector Transfection and Reporter Assay
The cells were transfected by TurboFect Transfection
Reagent (Thermo Scientific, Pittsburgh, PA, USA) ac-
cording to the manufacturer’s instructions. The total
amount of DNA for each experiment was matched to
equal with their individual backbone vector. After trans-
fection, the lysates of experimental cells were harvested
for luciferase assay system following the manufacturer’s
instructions (Promega, Madison, WI, USA). The 50 μL
of cell lysate, 50 μL of luciferin, and 180 μL of lucif-
erase assay reagent were injected into a luminometer
tube. After votexing, the tube was placed in the
luminometer and luciferase activity measured.
Pre-miR-135a and Antisense of miR-135a (A-135a)
-Inducible Stable Cells
The primers for PCR using pre-miR-135a forward (5′-AgeI-
AGGCCTCGCTGTTCTCTATGGC-3′) and pre-miR-135a
reverse (5′-PmeI-TGTCCCCGCCGTGCG-3′) to generate
pre-miR-135a construction in pAS4w.1.Pneo, a tetracycline-
inducible system of lentiviral expression vector. The A-135a
construction in pLAS1w.3xLacO, a lentiviral expression vec-
t o r , u s e d t h e DNA f r a gmen t a s f o l l ow s : 5 ′ -
TATGGCTTTTTATTCCTATGTGACTCGAGTCACATAG-
GAATAAAAAGCCATATTTTT-3′. Stable U373MG cells
containing Pre-miR-135a and A-135a were generated by
pLAS.AS3w.aOn.Pbsd lentiviral infectants and parental
U373MG cells, respectively. Doxycycline (2 μg/mL) was
used to induce miR-135a expression. IPTG (500 μM) was
used to induce A-135a expression. The lentiviral expression
vectors were obtained from the National RNAi Core Facility
located at the Genomic Research Center of Institute of Molec-
ular Biology, Academia Sinica (Taiwan).
Western Blot Analysis
For Western analysis, cells were lysed with modified RIPA
buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM
EDTA, 1 % Nonidet P-40, 0.25 % sodium deoxycholate,
1 mM PMSF, aprotinin 1 μg/mL, and leupeptin 1 μg/mL].
Lysates were resolved on a sodium dodecyl sulfate (SDS)-
containing 10 % polyacrylamide gel, transferred to
polyvinylidene difluoride (PVDF) nylon membrane and
probed with anti-THBS1(1:1000), anti-CEBPD (1:2000),
anti-α tubulin (1:10,000) at 4 °C overnight. Specific bands
were detected by a horseradish peroxidase-conjugated anti-
body specific for either rabbit or mouse IgG (1:3000) and
revealed by an enhanced chemiluminescence (ECL) Western
blot system from Pierce (Rockford, IL, USA).
Lentiviral Knockdown Assay
Virus was produced from Phoenix cells by co-transfection of
the various shRNA expression vectors in combination with
pMD2.G and psPAX2. After determining the viral infection
efficiency, 10 M.O.I. of lentivirus containing shβ-
galactosidase (shLacZ) or shCEBPD were used to infect
U373MG cells for 48 h. In all lentiviral experiments, medium
containing uninfected viruses was removed before conducting
further assays. The shRNA sequences in lentiviral expression
v e c t o r s s h o w n a s f o l l o w s : s h L a c Z , 5 ′ -
CCGGTGTTCGCATTATCCGAACCATCTCGAGATGGT-
TCGGATAATGCGAACATTTTTG-3′ and shCEBPD, 5′-
CCGGGCCGACCTCTTCAACAGCAATCTCGAGATTG-
CTGTTGAAGAGGTCGGCTTTTT-3′. The lentiviral knock-
down expression vectors were obtained from the
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National RNAi Core Facility located at the Genomic
Research Center of Institute of Molecular Biology, Ac-
ademia Sinica (Taiwan).
Chromatin Immunoprecipitation Assay
The chromatin immunoprecipitation (ChIP) assay was carried
out essentially as described by Wang et al. [34]. Briefly,
U373MG cells were treated with 1 % formaldehyde for
15 min. The cross-linked chromatin was then prepared and
sonicated to an average size of 500 bp. The fragmented
gDNA-protein complex was immunoprecipitated with anti-
bodies specific for CEBPD or control rabbit immunoglobulin
G at 4 °C overnight. After reversal of the cross-linking, the
immunoprecipitated chromatin was amplified by primers re-
lated to the specific regions of the target genes genomic locus.
The primers are as follows: FR-211 forward, 5 ′-
TCCTCTACTGGCCCTTTAGTCCCTG-3′ and FR-211 re-
verse, 5′-AGCTGGTTCTCAGCTGAAACAAAGA-3′; FR-
250 forward, 5 ′-AGAGACAGAGACAGATAGGA
A G C A A - 3 ′ a n d F R - 2 5 0 r e v e r s e , 5 ′ -
ACAGAAAAGTTGCCAGAATAGTGAT-3′. The amplified
DNA products were resolved by agarose gel electrophoresis.
In Situ Hybridization
Non-radioactive in situ hybridization was performed on
10 μm sections from mouse brain tissue blocks using the
digoxigenin-labeled locked nucleic acid-modified detection
probe (20 μM; 5′-TCACATAGGAATAAAAAGCCATA-3′;
Exiqon, Tustin, CA) complementary to mature miR-135a
and IsHyb in situ hybridization kit (BioChain, Hayward,
CA) following the protocol from Exiqon. Briefly, 10 μm sec-
tions were deparaffinized, hydrated, and treated with protein-
ase K (10 μg/mL; QIAGEN) at 37 °C for 15 min and fixed
with 4 % paraformaldehyde for 20 min. The sections were
incubated in pre-hybridization solution at 50 °C for 3 h and
then in hybridization solution with digoxigenin-labeled,
locked nucleic acid-modified miR-135a probe at 50 °C
for 16 h. The sections were incubated in the phosphate-
buffered saline diluted anti-digoxigenin-AP antibody
(1:100) at room temperature for 1 h, washed with 2×
standard saline citrate (SSC), 1.5× SSC, 0.2× SSC, in-
cubated in blocking solution for 1 h at room tempera-
ture, washed with phosphate-buffered saline three times,
then washed with 1× alkaline phosphatase buffer twice.
The NBT/BCIP solution was used for visualization of
hybridization signal.
Treatment of AppTg Mice with Antagomirs
Mice were anesthetized by intraperitoneal injection of chloral
hydrat (4 mg/kg) and then positioned in a stereotaxic
apparatus. Using a 30-guage Hamilton syringe, 1 μL of
phosphate-buffered saline containing 0.5 nmol of the
antagomir Cy3-labeled AM135a or a scrambled
antagomir (RiboBio ,Guangzhou, China) was injected
over 5 min into the third ventricle at the following coor-
dinates: antero-posterior, −1.06 mm; medio-lateral,
0.00 mm; and dorso-ventral, −2.4 mm from the bregma.
The needle was left in place for another 10 min and then
gently removed.
Morris Water Maze Test
The training apparatus was a circular white pool (120 cm
in diameter) containing water at 24 °C. A platform
(10 cm in diameter) was submerged 1 cm under the
water surface. Before the test, mice were first trained to
swim and climb on to the platform. For the hidden plat-
form trial, four sessions were performed (four trials per
session per day were carried out). Mice were allowed to
search for the platform for 120 s. If the mice did not find
the platform within 120 s, they were gently guided to it.
All mice were allowed to remain on the platform for
20 s. The time spent to reach the hidden platform was
recorded.
Results
Role of Astrocytic CEBPD in Neuron Apoptosis
and Spatial Learning in AppTg Mice
To find out whether the expression of Cebpd has direct in-
volvement in the spatial learning ability of mice, Morris water
maze was conducted using wild-type (Cebpd+/+), AppTg, and
AppTg/Cebpd−/− mice. As expected, AppTg mice have im-
paired spatial ability and failed to show improvement in laten-
cy to hidden even on day 4 (Fig. 1a). Interestingly, AppTg/
Cebpd−/− mice showed a time-dependent improvement in
their ability to navigate through the water maze. However,
AppTg/Cebpd−/− mice’s improvement in latency to hidden
was not as pronounced as wild-type mice. To find out whether
neuron viability has a role in AppTg/Cebpd−/− mice’s im-
provement in latency to hidden, we compared the staining of
caspase 3 in AppTg and AppTg/Cebpd−/− mice. As compared
to AppTg mice, the staining of caspase 3 was greatly attenu-
ated in AppTg/Cebpd−/− mice (Fig. 1b). To quantitatively
determine if Cebpd has a role in inflammation-
dependent cell viability, MTT assay was conducted in
primary Cebpd−/− neurons treated with IL-1β. To our
surprise, the primary Cebpd−/− neurons did not enhance
their cell viability as compared to primary Cebpd+/+
neurons, upon IL-1β treatment (Fig. 1c). Thus, we test-
ed whether astrocytic CEBPD was responsible for the
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viability of neuron instead. To address this issue, con-
ditioned media of IL-1β-pretreated primary wild-type or
Cebpd−/− astrocytes were incubated with primary neuron
cells. The survival and neurite outgrowth of neurons
showed little difference between Cebpd−/− and wild-
type neurons, if IL-1β pretreated CM from wild-type
astrocytes were used. However, upon incubation of the
CM from IL-1β-pretreated primary Cebpd−/− astrocytes,
the survival and neurite outgrowth of Cebpd−/− neurons
were attenuated (Figs. 1d and S1).
CEBPD Represses THBS1 Transcription
in Astrocytes
Astrocyte-secreting neurotrophic factors are essential
for neuronal survival and synaptic plasticity. Our global
profiling assay showed that THBS1, a neurotrophic
factor, was repressed in U373MG cells expressing
CEBPD (Table 1). The possibility that CEBPD can
directly repress the expression of THBS1 in U373MG
cells was tested by transfection with the zinc-inducible
CEBPD expression vector. RT-PCR and Western blot
studies found that overexpression of CEBPD lead to
decrease in expression of THBS1 (Fig. 2a). Thus, we
looked at whether IL-1β treatment has an effect on
THBS1 expression. Consistently, it was found that IL-
1β induced expression of CEBPD, leading to decrease
in THBS1 expression (Fig. 2b). To find out whether
CEBPD depletion can lead to an opposite effect as
compare to CEBPD overexpression, IL-1β-treated
U373MG cells were infected with two different shRNA
against CEBPD. It was found that knock down of
CEBPD can lead to increase in THBS1 expression in-
stead (Fig. 2c). Finally, the THBS1 repressive effect of
CEBPD was examined in mouse primary astrocytes
Fig. 1 Neuronal apoptosis and spatial learning ability in AppTg/Cebpd−/
− mice. a Spatial learning ability of wild-type (WT; C57BL/6), AppTg,
and AppTg/Cebpd−/− mice. Time required by WT (n=5), AppTg (n=5),
and AppTg/Cebpd−/− (n=3) mice to reach the hidden platform (latency to
hidden) was analyzed in the Morris water maze. b The apoptosis of
neurons was attenuated in AppTg/Cebpd−/− mice. The brain tissues were
subjected to immunofluorescence staining with the antibody recognized
NeuN or cleaved caspase 3 (cCap3; active caspase 3). Scale bar=
100 μm. c Primary Cebpd−/− neurons have no effect to reverse IL-1β-
induced cell death. The MTT assay was conducted as indicated. (d) At-
tenuated Cebpd expression in primary astrocytes does not contribute to
neuronal death. The conditioned medium came from either IL-1β-
pretreated primary WT or Cebpd−/− astrocytes. Primary cortical neurons
in WT and Cebpd−/− mice were seeded and grown on coverslips with the
mixture medium (9:1) of neuronal maintenance medium and above con-
ditioned medium for 72 h. The experimental neurons were performed
with immunofluorescence staining by anti-MAP2 antibodies for morpho-
logical examination and anti-cleaved caspase 3 (cCap3) antibodies for
cell death detection. Scale bar=100 μm. Data represent two independent
experiments with three mice/group in B or three independent experiments
in c and d. Data are expressed as mean±SEM by a Student’s t test.
(*P<0.05; **P<0.01; ***P<0.001; NS not significant)
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(Fig. 2d). Treatment of mouse primary astrocytes with
either TNFα or IL-1β can both lead to increase expres-
sion of CEBPD and a decrease in expression of
THBS1. Interestingly in Cebpd−/− primary astrocytes,
it was observed that there is a constantly high expres-
sion of Thbs1.
CEBPD Activates miR-135a Transcription
To explore which miRNAs are regulated by CEBPD in
astrocytes, we conducted a microarray profiling to
identify the CEBPD-regulated miRNAs (Table 2). In-
terestingly, miR-135a, a putative THBS1 mRNA bind-
ing suppressor, was observed to be upregulated by
CEBPD in the global profiling of miRNA. To find
out if CEBPD expression has direct correlation with
miR-135a expression, we investigated the expression
of miR-135a in U373MG cells either by overexpres-
sion of CEBPD or knock down of CEBPD. We ob-
tained a consistent result in which the overexpression
of CEBPD results in increasing expression of miR-
135a (Fig. 3a), while knock down of CEBPD results
in reduce expression of miR-135a upon IL-1β stimu-
lation (Fig. 3b). Subsequently, we explored whether
CEBPD still regulate miR-135a in primary astrocytes.
It was observed that the expression of miR-135a still
increased upon IL-1β treatment in primary Cebpd+/+
but not in Cebpd−/− astrocytes (Fig. 3c). Next, we
wished to find out how CEBPD can increase the ex-
pression of miR-135a. Since miR-135a is located at
intron 1 of GLYCTK-AS1-001 gene, we first made sure

















hsa-mir-135a 1.6 THBS1 0.57 hsa-miR-30c 0.59 ME1 1.64
SERPINC1 0.1 hsa-miR-24 0.62 ADAMTS 5 1.54
hsa-mir-1254 1.6 ETV7 0.55 BCL2L11 1.54
hsa-mir-1321 1.7 BAX 0.65 PDGFRA 1.51
BCL2L1 0.62 hsa-miR-17 0.64 ETV1 1.53
SYK 0.6 hsa-miR-320 0.64 ETV1 1.53
DTX1 0.65 KITLG 1.85
hsa-mir-198 1.74 DTX 0.65 hsa-miR-320b 0.64 ETV1 1.53
KITLG 1.85




hsa-miR-29b 0.65 BMF 1.51
PTX3 1.86
hsa-miR-15b 0.66 ADAMTS5 1.54
ITGA2 1.68




hsa-miR-19b 0.68 ABCA1 1.89
ID2 1.51
hsa-miR-23a 0.68 CA2 1.92
SLC1A1 1.56
TNFAIP6 1.65
hsa-miR-29a 0.68 BMF 1.51
PTX3 1.86
hsa-miR-29a 0.69 RGS2 1.91
hsa-miR-29a 0.69 RHOU 1.61
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that increase expression of CEBPD can indeed induce
the expression of GLYCTK-AS1-001 t ranscripts
(Fig. S2). We conducted a luciferase activity assay
and found that the native GLYCTK-AS1-001 reporter
was activated by CEBPD (Fig. 3d). However, the lu-
ciferase activity of the mutated GLYCTK-AS1-001 re-
porter was attenuated in contrast to native one. Thus,
we looked at whether CEBPD can directly bind to the
promoter of GLYCTK-AS1-001 by a chromatin-IP
(ChIP) assay (Fig. 3e). The result showed that indeed
CEBPD can bind to the region corresponding to our
primers.
miR-135a Can Target to THBS1 (Human)/Thbs1
(Mouse) 3′UTR and Contributes to the Repression
of THBS1/ Thbs1
To verify that miR-135a can indeed repress the expression of
THBS1, we infected a DOX-inducible miR-135a expression
system into primary astrocytes (Fig. 4a) and U373MG cells
(Fig. 4d). In both studies, we found that increase expression of
miR-135a attenuates the level of THBS1. Our recent study
demonstrated that prostaglandin 2 (PGE2) could repress
THBS1 3′UTR reporter activity through a miR-135a binding
motif. Two miR-135a binding motifs were identified in Thbs1
Fig. 2 THBS1 transcription is repressed by CEBPD in astrocytes. a
CEBPD contribute to THBS1 mRNA and protein degradation.
U373MG cells stably transfected with the zinc-inducible CEBPD expres-
sion vector and then incubated in the presence or absence of 100 μM
ZnSO4 for 6 h. RT-PCR and Western blot analysis were performed to
examine the expressions of THBS1 mRNA and protein. b THBS1 ex-
pression is suppressed after IL-1β treatment. U373MG cells were treated
with 5 ng/mL IL-1β for 3 h and then RT-PCR assay and Western blot
analysis were performed to examine the expressions of THBS1 mRNA
and protein, respectively. c CEBPD participates in IL-1β repressed
THBS1 transcription. U373MG cells were infected with lentivirus of
sh-galactosidase (shLacZ) or shCEBPD (shD1, shD2) and then treated
with IL-1β for 3 h. Total RNA or cell lysates were harvested for RT-PCR
orWestern blot analysis. d Loss of CEBPD in primary astrocytes reverses
IL-1β-attenuated Thbs1 expression. Primary Cebpd+/+ (WT) and
Cebpd−/− (CdKO) astrocytes were treated with 20 ng/mL TNFα, or
5 ng/mL IL-1β for 3 h, then the RT-PCR and Western blot were per-
formed to examine the expression of Thbs1 mRNA and protein,
respectively
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3′UTR. To confirm that Thbs1 3′UTR is indeed targeted by
miR-135a, we constructed luciferase reporter plasmids that
contained native or mutated seed sequences of Thbs1 3′
UTR. The reporter assay were conducted by co-transfecting
various mouse Thbs1 3′UTR reporters with miR-135a expres-
sion vector. We found that miR-135a repressed the native
Thbs1 3′UTR reporter activities, but these effects were lost
in construct with individual mutations of miR-135a binding
motifs (Fig. 4b). Similar results were also obtained from
co-transfecting various THBS1 3′UTR reporters with
CEBPD, pre-miR-135a expression vectors, or IL-1β
stimulation (Fig. 4d). Next, we investigated whether in-
hibition of miR-135a can lead to the opposite effect of
increasing THBS1 expression. We found that expression
of antisense of miR-135a (A-135a) in primary astrocytes
(Fig. 4c) or miR-135a antagomir (AM135a) in U373MG
cells (Fig. 4f) can lead to increase THBS1 expression.
Interestingly, a dose-dependent increased in expression
of CEBPD was also found upon AM135a expression
in U373MG cells.
Attenuated CEBPD and miR-135a in Astrocytes
Restores the Neuronal Neurite Outgrowth
It has been found that the growth of neurite decrease during
inflammation. We wished to determine whether knock out of
CEBPD in astrocyte could still lead to growth of primary
neurons upon IL-1β treatment. Conditioned medium from
primary Cebpd+/+ or Cebpd−/− astrocytes with or without
IL-1β treatment was added to primary neurons for 48 h. It
was found that neurons showed a reduction in length upon
incubation with CM containing Cebpd+/+ astrocytes with IL-
1β treatment, but there were no changes in length of primary
neurons upon incubation with CM containing Cebpd−/− astro-
cytes with IL-1β treatment (Fig. 5a). Consistently, we also
found that there is reduction in the length of neurons when
incubated with CM containing either U373MG cells overex-
pressing either CEBPD or miR-135a (Fig. S3a, S3b). There is
also no change in the length of primary neurons upon incuba-
tion with CM containing either astrocytes (Fig. 5b) or
U373MG cells (Fig. S3c) expressing antisense of miR-135a
(A-135a).
Intracerebral Injection of miR-135a Neutralizing
Antagomir Decreases Neuronal Apoptosis
and Enhances Spatial Learning Ability in AppTg
Mice
We wished to determine whether AM135a could be used as a
therapeutic agent on AppTg mice. First, we investigated the
expression of miR-135a in mouse brain by in situ hybridiza-
tion. Enhanced expression of miR-135awas found in the brain
of a 12-month-old AppTg mice but not in AppTg/Cebpd−/−
mice (Figs. 6a and S4). This result prompted us to inject a
Cy3-labeled AM135a (Cy3-AM135a) into the third ventricle
of the 12-month-old AppTg mice. We found that Cy3-
AM135a was distributed throughout the hippocampus and
surrounding tissue after 24 h (Fig. 6b). Consistent with our
previous studies, the whole brain level of Thbs1 showed in-
creased in expression at 1 week after the intraventricular in-
jection of 0.5 nmol AM135a (Fig. 6c). Next, we measured the
effect of AM135a on preventing neuronal apotoposis. It was
found that in brain section from AppTg mice injected with
AM135a, activated caspase 3 expression was attenuated and
co-localized with NeuN-positive markers (Fig. 6e). The
Table 2 CEBPD responsive miRNAs in U373MG cells
Upregulated Fold of change Downregulated Fold of change
hsa-miR-4314 2.2 hsa-miR-22 0.7
hsa-miR-788 1.9 hsa-miR-1979 0.7
hsa-miR-557 1.8 hsa-miR-200b 0.7
hsa-miR-198 1.7 hsa-miR-26b 0.7
hsa-miR-2116 1.7 hsa-miR-181b 0.7
hsa-miR-1321 1.7 hsa-miR-29a 0.7
hsa-miR1193 1.7 hsa-miR-138 0.7
hsa-miR-4299 1.7 hsa-miR-23a 0.7
hsa-miR-3131 1.6 hsa-miR-19b 0.7
hsa-miR-3190 1.6 hsa-miR-423 0.7
hsa-miR-4300 1.6 hsa-miR-515 0.7
hsa-miR-135a 1.6 hsa-miR-128 0.7
hsa-miR1254 1.6 hsa-let-7c 0.7
hsa-miR-514b 1.6 hsa-miR-1975 0.7
hsa-miR-1909 1.6 hsa-miR-708 0.7
hsa-miR-921 1.6 hsa-miR-15b 0.7
hsa-miR-3144 1.6 hsa-miR-103 0.7
hsa-miR-3125 1.5 hsa-miR-720 0.7
hsa-miR-1914 1.5 hsa-miR-16 0.7
hsa-miR-4257 1.5 hsa-miR-29b 0.7
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caspase activity of brain lysates from AppTg mice injected
with AM135a were also attenuated (Fig. S5). Finally, we car-
ried out Morris Water Maze test on AppTg mice treated with
AM135a. The escape latency of AppTg mice treated with
AM135a was significantly decreased after day 3 when
it was compared with mice treated with scrambled
antagomir (Fig. 6d).
Discussion
AD is a common neurodegenerative disease, which is associ-
ated with neuronal loss and severe cognitive deficit. Most
studies about AD have focused on neuronal dysfunction, but
few have concentrated on astrocytes’ role in pathogenesis of
AD. In AD patients and AppTg mice, CEBPD and Cebpd,
respectively, are found to be highly expressed in astrocytes
surrounding Aβ plagues [26, 20]. We found that AppTg/
Cebpd−/− mice showed a spatial learning improvement com-
pared with the AppTg mice. The Cebpd-deficient neuron was
not found to play a role in inflammation-induced apoptosis.
Since astrocytes are critical glial cells to support CNS by pro-
viding neurotrophic factors, we therefore tested whether cer-
tain neurotrophic factors were lost in activated astrocytes in
response to proinflammatory factors. The neurotrophic factor
THBS1 secreted from astrocytes was found to be attenuated in
IL-1β-treated astrocytes. We also found that the activation of
miR-135a transcription was responsive to transcription
factor CEBPD and represses THBS1 abundance in as-
trocytes. In addition to our recent discovery that miR-
135a plays an angiogenic role [27], we further demon-
strated that astrocytic miR-135a participates in inhibition
of neuronal viability and spatial learning ability in App-
Tg mice. We found that AppTg mice treated with
Fig. 3 miR-135a is a CEBPD responsive miRNA. a CEBPD induces
miR-135a expression. qRT-PCR and Western blot confirmed that miR-
135a levels and the expression of HA-tagged CEBPD protein from stable
U373MG cells with pMT-CEBPD expression vector, respectively. b
CEBPD participate in IL-1β-induced miR-135a expression. qRT-PCR
was performed with total RNA harvested from IL-1β-treated U373MG
cells with or without attenuation of CEBPD. c miR-135a expression is
unaltered in primaryCebpd−/− astrocytes. qRT-PCR was performed using
total RNA harvested from primary Cebpd+/+ and Cebpd−/− astrocytes
with or without IL-1β treatment. dCEBPD increases miR-135a promoter
activities. Schematic representation of reporter constructs with the
GLYCTK-AS1-001 promoter. The approximate location of putative
CEBPD-binding motif was indicated by open box. A luciferase activity
was conducted by co-transfected reporter and expression vectors as indi-
cated in U373MG cells. e CEBPD can directly bind to the GLYCTK-
AS1-001 promoter in vivo. A ChIP assay was performed with U373MG
cells treated with IL-1β. Chromatin of U373MG cells was separately
immunoprecipitated with specific antibody against CEBPD (CD) and
control IgG [14]. The schematic on the top indicated the location of the
primers used for detection of the GLYCTK-AS1-001 promoter by PCR.
The precipitated DNAs were amplified by PCR with primer (FR-211) on
the GLYCTK-AS1-001 promoter (−98/ +113) which contain putative
CEBPD-binding motif and negative control primer (FR-250). The data
represented the mean±standard error of three independent experiments,
each performed in triplicate. (*P<0.05, **P<0.01, ***P<0.001, Stu-
dent’s t test)
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AM135a had less dead neurons and showed improve-
ment in spatial learning ability.
Cebpd−/− mice are viable and have normal spatial learning
ability as compared to wild-type mice [35]. However, the loss
of Cebpdwas found to delay the progression and pathogenesis
of some inflammatory diseases [23, 25]. It implies that
CEBPD may not be essential in normal development, but
can play important roles in the pathogenesis of inflammatory
diseases. However, the details of CEBPD biology in
inflammation and inflammation-associated diseases remain
largely uninvestigated. Inflammation has been associated with
many neuronal diseases including AD, Parkinson’s disease
(PD), spinal cord injury, amyotrophic lateral sclerosis, and
multiple sclerosis [1]. Common physiological consequents in-
cluding the memory loss, dementia, and cognitive impairment
have been observed inmany neuroinflammatory diseases such
as AD, Parkinson’s and Huntington’s disease (HD) [36].
However, as mentioned above, the crosstalks, especially in
Fig. 4 miR-135a suppresses Thbs1/THBS1 transcription through its 3′
UTR region. a miR-135a attenuates the expression of Thbs1. Induced
miR135a in primary astrocytes with DOX-inducible miR-135a expres-
sion system; qRT-PCR and western blot analysis confirmed that miR-
135a, Thbs1 mRNAs, and proteins levels, respectively. b Two positions
of the Thbs1 3′-untranslated region are predicted to be targets of miR-
135a. The seed regions were indicated by the open box (upper panel).
Luciferase activity of reporter constructs was measured after co-
transfected with pre-miR-135a. c Antisense of miR135a (A-135a) antag-
onize the effects of Cebpd. Induced A-135a in primary astrocytes with
IPTG-inducible A-135a expression system and treated with or without
IL-1β treatment. d Induced miR-135a expression repress the THBS1
expression. In stable U373MG cells with DOX-inducible miR-135a ex-
pression system, the expression of miR-135a and the level of THBS1
mRNAs and proteins were examined by qRT-PCR, RT-PCR, andWestern
blot, respectively. e IL-1β and CEBPD suppresses THBS1 transcription
via miR-135a binding motif. The seed region was indicated by the open
box (upper panel). Luciferase activity of reporter constructs was measured
after co-transfected with pre-miR-135a, CEBPD expression vectors, or
treated IL-1β. f Antagomir of miR135a (AM135a) dose-dependently
antagonized the effects of CEBPD. AM135a or scramble antagomir were
transfected into the U373MG stable cells with zinc-inducible CEBPD
expression system and then incubated in the presence or absence of
100 μM ZnSO4 for 6 h. RT-PCR and Western blot analysis were per-
formed to examine the expressions of THBS1 mRNA and protein. The
data represent themean±standard error of three independent experiments,
each performed in triplicate. (*P<0.05, **P<0.01, Student’s t test)
Mol Neurobiol (2016) 53:4173–4188 4183
response to the activation of astrocytic CEBPD, between as-
trocytes and neurons in the inflamed brains have not been
characterized.
Previously, we provided evidences to demonstrate that the
activation of astrocytic CEBPD can contribute to inhibition of
phagocytosis, promotion of microglia migration, and
chemoattraction [26, 24]. The reduced extracellular level of
astrocytic THBS1 could be caused by amyloid-beta (Aβ) and
in Down syndrome, a disorder with a strong predilection for
the development of AD [37, 38]. Our study showed a coinci-
dent result that the THBS1 abundance is attenuated in AD
patients [39]. Accordingly, decreased neuronal neurite out-
growth, survival, and synaptophysin levels were also reported
to be associated with both knock down or knock out of
THBS1 [40, 37]. We found that the activation of astrocytic
CEBPD contributed to repression of neurotrophic factor
THBS1 abundance, which could result in the shortened
neurite length and death of neurons. Moreover, we revealed
that the CEBPD-upregulated miR-135a can target to THBS1-
3′UTR and resulted in its mRNA and protein degradations.
Dystrophic neurites are a hallmark in the brain of AD and
associated with mental decline and dementia [41]. Previous
Fig. 5 Astrocytic CEBPD and miR-135a regulate the extension of pri-
mary cortical neurons. a CEBPD in astrocytes reduces neuronal neurite
length. Conditioned medium from primary Cebpd+/+ or Cebpd−/− astro-
cytes with or without IL-1β treatment were subjected to exam Thbs1 by
Western blot and added to primary neurons for 48 h. b Attenuated miR-
135a in astrocytes restore the neuronal neurite outgrowth. Conditioned
medium from primary astrocytes infected with IPTG-inducible A-135a
expression system with or without IL-1β treatment were subjected to
exam Thbs1 by Western blot and added to primary neurons for 48 h.
Neurons were stained with mouse anti-MAP2 Abs for morphological
examination. Scale bar=100 μm. ImageJ software was used to quantifi-
cation micrometers of neurite length /neuron. Quantification of relative of
neurite length/neuron. (*P<0.05, **P<0.01, Student’s t test)
Fig. 6 The in vivo effects of AM 135a. a miR-135a expression increase
in the brain tissues of AppTg mice. miR-135a signal was detected by in
situ hybridization in the hippocampus and cortex of WT, AppTg, and
AppTg/Cebpd−/− mice. Scale bar=200 μm. b Cy3-AM135a efficiently
injected into AppTg mice. Twelve-month-old AppTg mice were injected
in the third ventricle with Cy3-labeled AM135a. At 24 h, fluorescence for
Cy3-AM135a was distributed throughout the hippocampus and
surrounding tissues. Cy3 fluorescence was not detected in control
(noninjected) brains. Insets show magnified views of the regions
indicated with arrows. Nuclei were stained with DAPI. c AM135a
significantly increased the whole brain level of Thbs1. Western blot
analysis conducted to detect Thbs1 of AppTg mice injected with
AM135a and the scramble antagomir at 1 week after the injection. d
AM135a improved the spatial learning ability of AppTg mice.
Intraventricular injected AppTg mice of AM135a (AppTg-AM135a) or
scramble antagomir (AppTg-Scramble). Morris water maze test for
spatial learning were performed 1 week after injection. Time required
by WT (n=5), AppTg-AM135a (n=5), and AppTg-Scramble (n=5)
mice to reach the hidden platform (latency to hidden) were analyzed. e
Cleavage caspase 3 (cCap3) expression was reduced in AppTg mice
treated with AM135a. The brain tissues were subjected to
immunofluorescence with anti-NeuN and anti-cleaved caspase 3
(cCap3). Scale bar=100 μm. Data are expressed as mean±SEM by a
Student’s t test. (*P<0.05; **P<0.01; ***P<0.001; NS not significant)
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studies showed that Aβ contribute to neurite degeneration in
cultured neurons and ultimately result in neuronal death [42,
43]. In addition to proinflammatory cytokines IL-1β and
TNFα, the treatment of Aβ also induced CEBPD activation
in astrocytes [26]. The results of neurons growing in the CM
from astrocyte expressing CEBPD or miR-135a provided a
novel mechanism to explain the reduced neuronal neurite
length and survival commonly observed in AD or other
neuroinflammatory diseases. It also provided a new evidence
for the communication between astrocytes and neuron in in-
flamed brain, especially in astrocyte-mediated cognitive loss.
Moreover, AM135a, the antagomir neutralizing miR-135a,
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could enhance THBS1 levels to prevent neuronal loss and
improve the learning ability in AppTg mice. The results indi-
cated that administration of AM135a could be a therapeutical-
ly effective treatment for AD patients.
Previous studies have identified that several miRNAs in the
brain are associated with AD, HD, PD, neuroviral infections,
and schizophrenia [44, 45]. Upregulation of miR-135a was
detected in the cerebrospinal fluid (CSF) of AD patients and
a microarray profile of the brain of AD mice [46, 47]. miR-
135a is a novel CEBPD responsive gene and first identified to
regulate THBS1 transcription. The results showed the first
evidence of miRNA-dependent dysregulation of THBS1 gene
involved in the pathogenesis of AD. Consistent with previous
studies [46, 47], our in situ hybridization result also demon-
strated that miR-135a was increased in the cortex and hippo-
campus of AppTg mice. Whereas, a recent study showed that
miR-135a targeted to beta-site amyloid precursor protein-
cleaving enzyme 1 (BACE1) in neuron cells and downregu-
lated in CSF and serum of AppTg mice [48]. The inconsistent
results indicated that the regulation of miR-135a could be in a
cell-type specific manner or because the variations of speci-
mens of AD patients and age of the AppTg mice. In addition,
BACE1 is majorly expressed and function in neuron cells.
However, miR-135a is a glia-enriched miRNA and low in
normal neuron cells [49]. Therefore, the contribution and im-
pact of miR-135a-mediated BACE1 repression in AD patients
need to be further verified.
In this study, we provided a result of CEBPD-regulated
miRNAs in astrocytes (Table 2). In addition to miR-135a,
several CEBPD-downregulated miRNAs including miR-9,
miR-19b, miR-29a/b-1, miR-16, and miR-107 were found to
be repressed in neurodegenerative diseases [50, 51]. Among
them, the expression level of miR-9, miR-29a/b-1, and miR-
107 was also reported to be negatively correlatedwith BACE1
in AD pathogenesis [52–54]. The attenuation of miR-9 and
miR-29a were further found in HDmice, which resulted in the
increase of transcription factor REST, a repressor of neuro-
trophic factor BDNF transcription [31]. In addition, with re-
spect to PD, miR-19b, miR-29a, and miR-16 were decreased
in sporadic and familial late-onset PD [55]. However, the spe-
cific location and regulation of above miRNAs in brain and
their specific function in astrocytes still pose an open question
for a further investigation. Furthermore, the links between
CEBPD responsive miRNAs and putative downstream genes
(Table 2) also provide interesting candidates for inhibiting
release of neurotrophic factors or producing neurotoxins.
Artemin (ARTN) is a potent neurotrophic factor for the pe-
ripheral nervous system and has great potential for the treat-
ment of neuropathic pain [56]. We found that miR-1914 could
be induced by CEBPD and is predicted to target the ARTN 3′-
UTR region. In addition, neurotoxic factor nitric oxide gener-
ated via iNOS was found in postmortem brains of AD and PD
patients [57]. CEBPD reduced the levels of miR-26b, miR-
29a, and miR-128 that are predicted to target inducible nitric
oxide synthase [10]. Therefore, the dissection of astrocytic
CEBPD involvement in inflamed brains that could reveal
more details for puzzling the complex issues in neurodegen-
erative disorders.
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